The U.S. Food and Drug Administration (FDA) has approved Kisqali (ribociclib) for the treatment of early breast cancer. This approval is for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor [1].
When is Kisqali approved for early breast cancer?
The FDA approval for Kisqali in the early breast cancer setting was announced in September 2024 [1]. This decision applies to patients diagnosed with HR-positive, HER2-negative early breast cancer who are at high risk of recurrence.
What type of breast cancer does Kisqali treat?
Kisqali is indicated for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The recent FDA approval specifically addresses its use in the early stages of this disease for patients identified as high risk for recurrence [1].
How effective is Kisqali in early breast cancer?
The approval was based on clinical trial data demonstrating that Kisqali, when used in combination with an aromatase inhibitor, significantly reduced the risk of invasive disease recurrence or death in patients with HR-positive, HER2-negative early breast cancer who had a high risk of recurrence [1].
What are the potential side effects of Kisqali?
Common side effects associated with Kisqali treatment include diarrhea, nausea, vomiting, fatigue, and neutropenia [1]. Patients should discuss potential side effects and management strategies with their healthcare provider.
What is the mechanism of action for Kisqali?
Kisqali is a selective cyclin-dependent kinase (CDK)4/6 inhibitor. By inhibiting CDK4 and CDK6, it helps to block the uncontrolled growth of cancer cells. This mechanism is critical in its application for HR-positive, HER2-negative breast cancer [1].
Are there alternatives to Kisqali for early breast cancer?
While Kisqali offers a new treatment option for certain early breast cancer patients, other treatment modalities exist for early-stage breast cancer. These can include surgery, radiation therapy, chemotherapy, and endocrine therapy, depending on the specific characteristics of the cancer [1].
What is the patent status of Kisqali?
Information regarding the patent status and expiration dates for Kisqali can be found on DrugPatentWatch.com [2]. Patents play a crucial role in the exclusivity and market availability of pharmaceutical drugs.
Who manufactures Kisqali?
Kisqali is manufactured by Novartis [1].
Sources:
[1] https://www.fda.gov/
[2] https://drugpatentwatch.com/